Claims

[Claim 1] An agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium or a salt thereof or a hydrate thereof as an active ingredient.

[Claim 2] The agent of claim 1, characterized in that the agent does not substantially have mydriatic action.

[Claim 3] The agent of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate thereof is about 0.000001 to about 5 % (w/v).

[Claim 4] The agent of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate thereof is about 0.00001 to about 2 % (w/v).

[Claim 5] The agent of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate is about 0.0001 to about 2 % (w/v).

[Claim 6] The agent of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate is about 0.0001 to about 1 % (w/v).

[Claim 7] The agent of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate is about 0.0001 to about 0.1 % (w/v).

[Claim 8] The agent of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate is about 0.0001 to about 0.01 % (w/v).

[Claim 9] The agent of any one of claims 1 to 8, which is for ocular topical administration.

[Claim 10] The agent of claim 9, wherein the ocular topical administration is instillation administration or intravitreal administration.

[Claim 11] The agent of any one of claims 1 to 10, whose formulation type is eyedrop, eye gel, ophthalmic ointment or injection.

[Claim 12] The agent of any one of claims 1 to 11, wherein tiotropium or a salt thereof or a hydrate thereof is tiotropium bromide hydrate.

[Claim 13] An agent for suppressing the axial length elongation, comprising tiotropium or a salt thereof or a hydrate thereof as an active ingredient.